TWILIGHT: Ticagrelor monotherapy 3 months post-PCI decreases bleeding regardless of age healio.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from healio.com Daily Mail and Mail on Sunday newspapers.
Elixir Medical Corporation: Elixir Medical Expands BIOADAPTOR Randomized Controlled Trial of DynamX Coronary Bioadaptor System Elixir Medical, a developer of innovative, drug-eluting cardiovascular devices, today announced that the BIOADAPTOR randomized controlled trial (RCT) is expanding to centers in Belgium and Germany. The BIOADAPTOR RCT is evaluating the DynamX Coronary Bioadaptor System, the first drug-eluting coronary artery implant that adapts to vessel physiology.
The BIOADAPTOR RCT is a multicenter, randomized, single-blind study enrolling 444 patients from 30 centers in Europe and Japan treated with the DynamX Bioadaptor in a 1:1 randomization to Resolute Onyx, a leading drug-eluting stent (DES). The primary endpoint of the study is target lesion failure at one year. Secondary endpoints include measures of the implants ability to accommodate vessel growth from disease progression and restore artery pulsatility in an imaging subset, as well as other major cardiovasc
First Patient Treated in Elixer Dynamx Coronary Bioadaptor Stent Technology
International trial compares Bioadaptor coronary stent designed to adapt to vessel physiology with stanard DES
The Elixer Dynamx Coronary Bioadaptor Stent technology uses a bioresorbable polymer that dissolves after three months and disconnected joints between numerous stent segments, allowing it to articulate and shape to the vessel and its movement.
April, 14, 2021 – Elixir Medical recently announced the first patient was treated in the BIOADAPTOR randomized controlled trial (RCT) of the DynamX Coronary Bioadaptor System, the first drug-eluting coronary stent that adapts to vessel physiology. It uses a drug-eluting bioresorbable polymer coating that dissolves after three months, which disconnects joints between segments of the metallic stent, allowing it to articulate with vessel movement and its natural shape.
indexmarketsresearchFebruary 4, 2021 25
As claimed to the given report,global Percutaneous Coronary Intervention (PCI) Devices market is assessed with
reference to type, application spectrum, and regional countryside.The Market report in its large database titled
Percutaneous Coronary Intervention (PCI) Devices Market. Further, it includes insights provided by the analysts and experts about the financial statements along with the company profiles, products, and services of all the key market players.The report investigates important factors related to the Global Percutaneous Coronary Intervention (PCI) Devices Market that are essential to be understood by new as well as existing players in the given market.The report highlights the important factors such as market share, profitability, sales, production, manufacturing, advertising, technological developments, key market players, regional segmentation and many other significant aspects related to the Global Percutaneous Cor